# QL1706 in the Treatment of Advanced Bone and Soft Tissue Sarcoma

> **NCT06939855** · PHASE2 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 45 (estimated)

## Conditions studied

- Bone and Soft Tissue Tumors

## Interventions

- **DRUG:** QL1706 (bispecific antibody targeting PD-1 and CLTA-4)

## Key facts

- **NCT ID:** NCT06939855
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-28
- **Primary completion:** 2027-05-01
- **Final completion:** 2028-05-01
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2025-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06939855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06939855, "QL1706 in the Treatment of Advanced Bone and Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06939855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*